Vaccine adjuvants: mechanisms and platforms.
Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. · 2023
Read Vaccine adjuvants: mechanisms and platforms. by Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10356842.txt.
Introduction
Zhao and co-authors reviewed vaccine adjuvants in 2023, the added parts that boost a vaccine's effect. A vaccine trains the immune system to fight a germ. An adjuvant makes that training stronger, yet how most of them work stayed unclear for years. New insight into the first wave of immune defence has begun to explain them.
Two broad kinds stand out in the review by Zhao. One kind sounds an alarm that wakes up cells which present the vaccine target to the immune system. The other kind acts as a carrier, holding the target longer or guiding it to lymph nodes. The review covers classic adjuvants and newer platforms with stronger effects. It ends with design choices for future vaccines.
Catalog record
| CREATOR | Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 153 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Vaccine adjuvants: mechanisms and platforms By Tingmei Zhao, Yulong Cai, Yujie Jiang, Xuemei He, Yuquan Wei, Yifan Yu, Xiaohe Tian Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01557-7 ABSTRACT Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific response, the adjuvants’ action mechanisms are beginning to be elucidated. Adjuvants can be categorized as immunostimulants and delivery systems. Immunostimulants are danger signal molecules that lead to the maturation and activation of antigen-presenting cells (APCs) by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) to promote the production of antigen signals and co-stimulatory signals, which in turn enhance the adaptive immune responses. On the other hand, delivery systems are carrier materials that facilitate antigen presentation by prolonging the bioavailability of the loaded antigens, as well as targeting antigens to lymph nodes or APCs. The adjuvants’ action mechanisms are systematically summarized at the beginning of this review. This is followed by an introduction of the mechanisms, properties, and progress of classical vaccine adjuvants. Furthermore, since some of the adjuvants under investigation exhibit greater immune activation potency than classical adjuvants, which could compensate for the deficiencies of classical adjuvants, a summary of the adjuvant platforms under investigation is subsequently presented. Notably, we highlight the different action mechanisms and immunological properties of these adjuvant platforms, which will provide a wide range of options for the rational design of different vaccines. On this basis, this review points out the development prospects of vaccine adjuvants and the problems that should be paid attention to in the future. INTRODUCTION Adjuvants are defined as various components that enhance the immunogenicity of vaccines when administered in conjunction with vaccine antigens (Fig. 1).1 Adjuvants can range from synthetic small molecule compounds to complex natural extracts and particulate materials.2 The first evidence of adjuvants appeared in 1926, when Alexander Glenny found that mixing aluminum salts with antigens and injecting them into guinea pigs induced more antibodies than administering antigens alone (Fig. 2).3 Subsequently, in the 1940s, Freund and his colleagues developed water-in-oil emulsions, which led to the creation of Freund’s adjuvants.4,5 However, Freund’s adjuvant is not licensed for use in human vaccines because of its toxicity to humans. Similar to Freund’s adjuvants, the use of bacterial lipopolysaccharide (LPS) adjuvants in human vaccines has been limited due to their local and systemic side effects. In fact, from the 1920s through the 1990s, only aluminum adjuvants were licensed, despite efforts to develop new adjuvants for human vaccines. It was not until 1997 that the oil-in-water emulsion MF59 was licensed in Europe as an adjuvant for influenza vaccines. In the following 20 years, four other adjuvants (AS04, AS03, AS01, and CpG ODN 1018) were licensed for use in vaccines, which changed the monotony of adjuvants for human vaccines.6 In addition, many other different classes of compounds had been evaluated as adjuvants during this time, including mineral salts, microbial products, emulsions, saponins, synthetic small molecule agonists, polymers, nanoparticles, and liposomes.7 They have shown to enhance the strength, breadth, and persistence of immune responses in preclinical and clinical studies.8Fig. 1Adjuvants enhance the immunogenicity of vaccines. a Vaccines without adjuvants induce modest production of T helper-polarizing cytokines, antibodies, and activated T cells. b In contrast, vaccines with adjuvants promote the maturation of more APCs, increase the interaction between APCs and T cells, promote the production of greater numbers and more types of T helper-polarizing cytokines, multifunctional T cells, and antibodies, leading to broad and durable immunity, as well as dose and antigen savings. This figure was created with BioRender (https://biorender.com/)Fig. 2Timeline of major events in the research history of vaccine adjuvants. This figure was created with BioRender (https://biorender.com/) Although adjuvants have long been widely used in vaccines, the mechanisms by which they enhance immune responses have not been well characterized. It was not until the revelation of the mechanism by which the innate immune response controls the adaptive immune response that scientists began to understand the action mechanisms of adjuvants.9 Adjuvants guide and enhance specific adaptive immune responses by targeting innate immune cells and activating pattern recognition receptors (PRRs) signaling pathways.10 Subsequently, it was discovered that some delivery materials can also act as adjuvants by enhancing adaptive immune responses through mimicking the size or spatial structure of natural pathogens to facilitate antigen uptake and presentation by antigen-presenting cells (APCs).11 Despite the above advances in the development of adjuvants, there is little systematic generalization and summary of the action mechanisms of adjuvants due to their broad definitions and complex mechanisms. Moreover, due to the lack of systematic and in-depth understanding of the mechanisms, characteristics, immune effectiveness, and application scenarios of the current adjuvant platforms, it is difficult to match and design appropriate adjuvants for specific vaccines. This has led current vaccines gradually showing shortcomings in their use, such as the inability to provide long-term protective immunity, weak immunity in elderly populations, and the inability to provide effective cellular immunity.12,13 Therefore, in order to solve these problems, this review attempts to summarize the mechanisms of adjuvants firstly. Then, the mechanisms, characteristics and application progress of the classical adjuvant platforms and the adjuvant platforms under investigation with potential development value, are summarized and described. In the final part of this paper, some possible future directions of adjuvants are discussed. This review is expected to provide an effective reference for further research on the mechanisms of adjuvants, rational use of existing adjuvants, and design and development of new adjuvants. THE MECHANISMS OF ADJUVANTS Adjuvants have been widely used in vaccines to promote the success of vaccination. Adjuvants enhance the adaptive immunity of vaccines by activating innate immune cells.10 The core concept is that adjuvants promote the generation of antigen presentation signals (signal 1) and co-stimulatory signals (signal 2) by activating APCs (Fig. 3). The antigen presentation signals are the antigen peptides-major histocompatibility complexes (MHC) that are presented on the surface of APCs after antigens have been taken up and processed. Co-stimulatory signals include co-stimulatory molecules (e.g., CD40, CD80, CD86) expressed on the surface of APCs and secreted inflammatory cytokines (e.g., IL-6, IL-10, IL-12, and TNF-α). The production of these two signals can strongly induce the activation of naive T cells, leading to an enhanced adaptive immune response.14,15 Immunostimulants, such as pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and chemically synthesized small molecule agonists of TLRs, can lead to signal 1 and signal 2 production by APCs. Delivery systems, such as lipid nanoparticles (LNPs), poly(lactide-co-glycolide) (PLGA), and caged protein nanoparticles, play a role by facilitating the presentation of antigens on MHC molecules (signal 1). Notably, some studies have shown that many nanoparticle delivery systems can directly target B cells to induce an optimally effective antibody response.1,7,11 In the following, we describe in detail the specific mechanisms by which immunostimulants and delivery systems exert their adjuvant efficacy.Fig. 3The core of the action mechanisms of adjuvants. Adjuvants are classified as immunostimulants and delivery systems. Immunostimulants such as PAMPs, DAMPs, and chemically synthesized small molecule agonists, provide danger signals (signal 0) to activate PRRs on APCs, thereby enhancing antigen presentation on MHC molecules (signal 1). In